Bayesian Capital Management’s Standard BioTools LAB Stock Holding History

Bayesian Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,700	Closed	-$17K	–	877
2022 Q2	$17K	Buy	+10,700	New	+$26.5K	﹤0.01%	735
2021 Q2	–	Sell	-13,649	Closed	-$62K	–	535
2021 Q1	$62K	Buy	+13,649	New	+$75K	0.01%	506
2020 Q4	–	Sell	-15,300	Closed	-$114K	–	569
2020 Q3	$114K	Buy	+15,300	New	+$106K	0.03%	475
2019 Q2	–	Sell	-25,870	Closed	-$344K	–	604
2019 Q1	$344K	Buy	+25,870	New	+$273K	0.07%	362
2016 Q2	–	Sell	-12,049	Closed	-$97K	–	478
2016 Q1	$97K	Buy	12,049 +900	+8%	+$6.49K	0.09%	313
2015 Q4	$121K	Buy	+11,149	New	+$109K	0.17%	209

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JCP

Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Bayesian Capital Management's LAB Position: Q3 2022 in Review

Bayesian Capital Management sold out of Standard BioTools (LAB) in Q3 2022, closing a stake of 10,700 shares — an estimated $17K sold.

Bayesian Capital Management first reported a position in LAB in Q4 2015 and held it in 6 quarters. The position peaked at $344K in Q1 2019. 65 funds tracked by Wall St. Rank hold LAB as of Q3 2022.

Bayesian Capital Management reported no remaining Standard BioTools position as of Q3 2022 after selling out during the quarter.
Bayesian Capital Management sold 10,700 Standard BioTools shares in Q3 2022, an estimated $17K.
Bayesian Capital Management first reported a position in Standard BioTools in Q4 2015 and held it in 6 quarters.
Bayesian Capital Management's Standard BioTools position peaked at $344K in Q1 2019.
65 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.